Dr. Fanale on Clinical Trials for T-Cell Lymphoma

Michelle A. Fanale
Published: Monday, Feb 27, 2017



Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

In the relapsed setting for patients with T-cell lymphoma, there are several doublet-based trials with romidepsin (Istodax), Fanale explains. There are plans to do randomized trials to compare 2 doublets versus romidepsin on its own.

Right now, a lot of the active clinical trials in the frontline setting look at a combination of chemotherapy plus one of the targeted agents, states Fanale. One of the eagerly awaited clinical trials is the ECHELON-2 trial, which focused on the combination of brentuximab vedotin (Adcetris) with CHP compared with CHOP, which is the standard of care. It has now completed enrollment but has not yet met its primary endpoint for progression-free survival.
 


Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

In the relapsed setting for patients with T-cell lymphoma, there are several doublet-based trials with romidepsin (Istodax), Fanale explains. There are plans to do randomized trials to compare 2 doublets versus romidepsin on its own.

Right now, a lot of the active clinical trials in the frontline setting look at a combination of chemotherapy plus one of the targeted agents, states Fanale. One of the eagerly awaited clinical trials is the ECHELON-2 trial, which focused on the combination of brentuximab vedotin (Adcetris) with CHP compared with CHOP, which is the standard of care. It has now completed enrollment but has not yet met its primary endpoint for progression-free survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted TherapiesMar 31, 20181.5
Publication Bottom Border
Border Publication
x